Background
==========

Osteoarthritis (OA) is one of major degenerative diseases that cause chronic pain in middle-aged to older adults around the world \[[@b1-medscimonit-25-6649]\]. It is characterized by progressive degeneration of the cartilage and extracellular matrix (ECM) \[[@b2-medscimonit-25-6649],[@b3-medscimonit-25-6649]\]. OA progression has been linked to obesity, inflammation, and mechanical stress \[[@b4-medscimonit-25-6649],[@b5-medscimonit-25-6649]\]. The specific molecular mechanism of OA remains unclear, but it is clearly complex. Therefore, fully elucidating the pathogenesis of OA will promote the development of novel treatment strategies for this common disease.

In healthy cartilage, the chondrocyte has a very low turnover, which ensures the metabolic balance of ECM, such as aggrecan with a half-life of 3--24 years \[[@b6-medscimonit-25-6649]\] and collagen with a half-life of 100 years or more \[[@b7-medscimonit-25-6649]\]. By maintaining the internal pressure of the cartilage, the ECM constitutes a stable hydrodynamic system which maintains cartilage function \[[@b8-medscimonit-25-6649]\]. Accordingly, chondrocytes are crucial in cartilage matrix repair. The metabolic balance of ECM is mainly controlled by catabolic enzyme produced and released by cartilage chondrocytes, including matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS). Evidence of the importance of the catabolic activities in the pathogenesis of OA \[[@b9-medscimonit-25-6649]\] comes from studies showing that several collagenolytic MMPs are upregulated in the chondrocytes of OA patients \[[@b10-medscimonit-25-6649]\], and that there is high-level expression of aggrecanases ADAMTS-1, -4, -5, -9, and -15 in OA cartilage \[[@b11-medscimonit-25-6649]\]. The excessive apoptosis of chondrocytes is another primary feature of the cartilage degeneration seen in OA \[[@b12-medscimonit-25-6649]--[@b14-medscimonit-25-6649]\] whereas the inhibition of pro-apoptotic caspase signaling attenuates OA progression \[[@b15-medscimonit-25-6649]\].

Several research studies have suggested that the inflammatory response plays an essential role during the development of OA. Levels of the pro-inflammatory factors tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1β are significantly upregulated in OA cartilage and mediate cartilage degeneration \[[@b16-medscimonit-25-6649]\]. Macrophages and other innate immune cells are key elements in the inflammation associated with OA progression \[[@b17-medscimonit-25-6649],[@b18-medscimonit-25-6649]\]. Macrophages sense harmful environmental conditions by targeting pathogen-associated molecular patterns or endogenous danger-associated molecular patterns. Recognition of these chemical disturbances contributes to the accumulation of inflammasomes and the subsequent release of IL-1β \[[@b19-medscimonit-25-6649]\], a vital part of the cytokine network related to OA \[[@b5-medscimonit-25-6649]\]. IL-1β is widely applied in studies of the pathophysiology of OA, to trigger the release of inflammatory cytokines as well as chondrocyte apoptosis \[[@b20-medscimonit-25-6649]\]. Regulation of the levels of several catabolic enzymes (MMPs or ADAMTS) is achieved by transcription factors, especially nuclear factor-kappa B (NF-κB) \[[@b21-medscimonit-25-6649],[@b22-medscimonit-25-6649]\].

Catalpol (CAT), an iridoid glycoside isolated from the root of *Rehmannia*, exerts protective effects against various diseases \[[@b23-medscimonit-25-6649]\]. In a transient global ischemia model, CAT was shown to participate in the regulation of apoptosis in hippocampal CA1 neurons, by regulating the levels of Bcl-2 and Bax \[[@b24-medscimonit-25-6649]\]. CAT also protects mice against renal ischemia/reperfusion injury, by regulating the PI3K/Akt-eNOS signaling and the inflammatory response \[[@b25-medscimonit-25-6649]\]. Given the established anti-apoptotic and anti-inflammatory effects of CAT, the present study was designed to explore its potential protective role in a rat model of OA involving the knee joint.

The potential effects of CAT in rats were explored by assessing the apoptotic and metabolic levels of the ECM in CAT-treated chondrocytes. We also examined whether the observed attenuation of cartilage degeneration by CAT was mediated by the NF-κB pathway. Our results demonstrate the potential value of CAT as the basis of potential strategies for the prevention and treatment of OA.

Material and Methods
====================

Reagents and antibodies
-----------------------

The CAT (purity \>98%) was supplied by the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). IL-1β was obtained from PeproTech. Primary antibodies (anti-cleaved caspase-3, anti-p65, anti-IκBα and anti-β-actin) were acquired from Cell Signaling Technology (Danvers, MA, USA), and those (anti-TNF-α and anti-IL-6) were supplied by Sigma-Aldrich (St Louis, MO, USA).

Chondrocyte culture and treatment
---------------------------------

The knee cartilage of Sprague-Dawley (SD) rats (body weight 180--220 g) was collected for chondrocyte culture. All animal experiments were operated in compliance with the standards of the Animal Care and Use Committee of Hainan Medical University (Haikou, China). Chondrocytes, isolated and cultured as previously described \[[@b26-medscimonit-25-6649]\], were used within the first 3 passages. The tissue was collected in 0.25% trypsin-EDTA for 30 minutes and then incubated with 0.2% collagenase-II for 4 hours. The isolated chondrocytes were suspended in Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% antibiotic, plated in 6-well plates (1×10^5^ cells) per well. After 2 days, the chondrocytes were treated for 1 day with IL-1β (10 ng/mL) with or without a combination of various concentrations of CAT (as shown in the Figures). The chondrocytes were then collected for real-time polymerase chain reaction (RT-PCR) and western blot.

Cell viability
--------------

Cell viability was monitored by Cell Counting Kit-8 (CCK-8) reagent with the manufacturer's instructions. Chondrocytes were seeded into a 96-well plate (5 x 10^3^ cells) per well and cultured for 1 day after being treated with CAT with or without a combination of IL-1β. Then the wells were washed, and 100 μL of DMEM containing CCK-8 solution (10 μL) was added to each well and incubated for another 2 hours. The values of absorbance in each well were recorded using a microplate spectrophotometer at 450 nm.

Quantitative RT-PCR
-------------------

The mRNA (2 μg) was isolated from chondrocytes using the TRIzol method using the manufacturer's protocol. Synthesis and amplification of cDNA were operated by usage of the Prime-Script RT-PCR kit and SYBR Premix Ex Taq (Roche Diagnostics GmbH, Penzberg, Germany). The gene levels were detected using the DDCt method and the value was normalized to the level of β-actin mRNA.

Western blot assay
------------------

Protein extractions from chondrocytes were performed using RIPA buffer and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on an 8--12% polyacrylamide gel. The protein (60 μg) was then transferred to previously blocked polyvinylidene difluoride membrane and probed overnight with primary antibodies (anti-TNF-α, anti-IL-6, anti-p65, anti-IκBα, anti-cleaved caspase-3, and anti-β-actin). The following day, the membrane was incubated for 1 hour with the secondary antibodies. The resulting signal was revealed and quantified by the ChemiDicTM XRS+Imaging System (Bio-Rad, Hercules, CA, USA).

Immunofluorescence staining
---------------------------

For collagen-II and p65 staining, the chondrocytes were plated in the glass coverslips into 6-well plates. After treatment, the slides were fixed using 4% paraformaldehyde (PFA) for 15 minutes, permeabilized in 0.1% Triton X-100 for 15 minutes, and incubated in 5% BSA for 1 hour before being treated with primary antibodies (anti-p65 and anti-collagen II). After an overnight incubation at 4°C, the specimens were treated with the secondary antibodies for 1 hour. Then slides were stained with DAPI (4′,6-diamidino-2-phenylindole) for another 10 minutes. The slides were viewed and imaged by a Nikon ECLIPSE Ti microscope (Nikon, Tokyo, Japan).

Immunohistochemistry analysis
-----------------------------

For cleaved caspase-3 staining, the specimens were fixed using 4% PFA and embedded in wax. After dewaxing and hydration, the samples were blocked by 3% H~2~O~2~ for 15 minutes and 5% bovine serum albumin (BSA) for 45 minutes before being treated with primary antibodies (anti-cleaved caspase-3). After an overnight incubation at 4°C, the specimens were treated with horseradish peroxidase (HRP) conjugated secondary antibody for 1 hour. Then slides were stained with hematoxylin for another 10 minutes. The slides were viewed and imaged by a light microscopy.

Model and treatment of OA
-------------------------

The protocol used in the animal experiments was in compliance with the standards of the Animal Care and Use Committee at Hainan Medical University. Fifteen 3-month-old male SD rats were supplied from the Animal Center of the Chinese Academy of Sciences (Shanghai, China). All rats were anesthetized via intraperitoneal injection of 2% pentobarbital (40 mg/kg). The right anterior cruciate ligament (ACL) was transected, and the right medial meniscus was resected aseptically \[[@b27-medscimonit-25-6649]\]. The sham group underwent the same surgical preparation but without ACL transection or meniscus resection. After operation, animals in the OA+CAT group received CAT (5 mg/kg/day; intraperitoneal injection) \[[@b28-medscimonit-25-6649]\].

Histological assay
------------------

Isolated right knee joints were fixed in 4% PFA for a day, underwent decalcification and dehydration, and then were embedded in paraffin. The specimens were cut into 4-μm thick sections for Safranin O-fast green staining to evaluate cartilage degeneration by light microscopy. The condition of the cartilage was also graded according to the Osteoarthritis Research Society International (OARSI) system \[[@b29-medscimonit-25-6649]\].

Statistical analysis
--------------------

Data were expressed as means ± standard error of the mean (SEM) of 5 independent experiments. A one-way analysis of variance (ANOVA) followed by Tukey's post-hoc test was used to for comparison between different group. A *P* value \<0.05 was considered statistically significant.

Results
=======

CAT decreased apoptosis in chondrocytes
---------------------------------------

Possible cytotoxic effects of CAT on chondrocytes were assessed by incubating the cells with various concentrations of CAT for 1 day. CCK-8 assay showed that there was no chondrocyte cytotoxicity at final CAT concentrations between 0 and 100 μg/mL. Thus, within this range, CAT had no effect on chondrocyte viability ([Figure 1A](#f1-medscimonit-25-6649){ref-type="fig"}). Moreover, at concentrations \<100 μg/mL, CAT exerted a remarkable protective effect in IL-1β-stimulated group ([Figure 1B](#f1-medscimonit-25-6649){ref-type="fig"}). Western blotting showed that CAT significantly reduced the expression of the pro-apoptotic protein cleaved caspase-3 in IL-1β-treated chondrocytes ([Figure 1C, 1D](#f1-medscimonit-25-6649){ref-type="fig"}). Together, the data revealed that CAT exerts a protective effect on chondrocytes.

CAT decreased the expressions of MMP-1, MMP-3, and MMP-13 in IL-1β-treated chondrocytes
---------------------------------------------------------------------------------------

IL-1β stimulation significantly triggered the mRNA and protein expression of MMP-1, MMP-3, and MMP-13 compared to the control group. The effect of CAT on the level of MMPs in mRNA and protein was tested by PCR and enzyme-linked immunosorbent assay (ELISA), respectively. A comparison with chondrocytes treated with IL-1β alone showed that CAT treatment resulted in statistically significant decreases in MMPs gene and protein expression ([Figure 2](#f2-medscimonit-25-6649){ref-type="fig"}).

CAT decreased the IL-1β-induced expression of ADAMTS-4 and ADAMTS-5 in chondrocytes
-----------------------------------------------------------------------------------

IL-1β-stimulated chondrocytes treated with CAT showed dose-dependent reductions in ADAMTS-4, and ADAMTS-5 gene and protein levels compared to chondrocytes induced by IL-1β alone ([Figure 3](#f3-medscimonit-25-6649){ref-type="fig"}).

CAT inhibited IL-1β-mediated catabolic activity on the levels of major ECM proteins in rat chondrocytes
-------------------------------------------------------------------------------------------------------

An immunofluorescence assay revealed a decrease in collagen II-positive staining in IL-1β-stimulated chondrocytes ([Figure 4A](#f4-medscimonit-25-6649){ref-type="fig"}), and that the effect was attenuated by CAT treatment. These results were confirmed by PCR, which showed that collagen II and aggrecan mRNA levels were downregulated by IL-1β exposure and that CAT treatment inhibited this response ([Figure 4B, 4C](#f4-medscimonit-25-6649){ref-type="fig"}).

CAT decreased the IL-1β-induced release of pro-inflammatory factors in chondrocytes
-----------------------------------------------------------------------------------

Compared to control unstimulated cells, IL-1β-induced chondrocytes produced significantly larger amounts of IL-6 and TNF-α. By contrast, CAT treatment decreased the amount of IL6 and TNF-α produced by IL-1β-stimulated group ([Figure 5](#f5-medscimonit-25-6649){ref-type="fig"}), indicating that CAT is able to attenuate IL-1β-induced inflammation.

CAT suppressed NF-κB pathway activation in IL-1β-stimulated chondrocytes
------------------------------------------------------------------------

To determine the molecular mechanism underlying CAT activity in IL-1β-treated chondrocytes, our work detected whether it was related to the NF-κB pathway. The expression of p65 and IκBα protein was investigated by western blot. IκBα is the upstream signaling protein of NF-κB, and its degradation of IκBα is an indicator of the signaling pathway activation. Compared with the control group, p65 was upregulated, and IκBα downregulated, in IL-1β-treated chondrocytes, indicating enhanced activity of the NF-κB pathway ([Figure 6A--6C](#f6-medscimonit-25-6649){ref-type="fig"}). Immunofluorescence assays showed clear and enhanced nuclear translocation of p65 in IL-1β-induced group. Translocation was reversed by CAT ([Figure 6D](#f6-medscimonit-25-6649){ref-type="fig"}), indicative of its ability to suppress the NF-κB pathway in IL-1β-induced chondrocytes.

CAT attenuated apoptotic level and ECM degradation in rat cartilage of OA
-------------------------------------------------------------------------

The histopathological situation in both the cartilage matrix and the articular structure of the rat knee joint were evaluated using Safranin O staining and quantified using the OARSI scoring system. The articular cartilage in the OA group exhibited remarkable degeneration, including cartilage erosion, as well as loss of ECM proteins and cells. The ability of CAT to considerably attenuate cartilage destruction in the OA group was supported by the OARSI score ([Figure 7A, 7B](#f7-medscimonit-25-6649){ref-type="fig"}). In the immunohistochemical assay, CAT clearly reduced the level of cleaved caspase-3 in the articular cartilage of the OA group ([Figure 7C](#f7-medscimonit-25-6649){ref-type="fig"}), consistent with the results of the *in vitro* experiments. These results demonstrated the significant protective effects of CAT*in vivo*.

Discussion
==========

OA is one of major degenerative joint diseases characterized by the dysfunction and excess apoptosis of chondrocytes. Genetic and environmental factors, as well as aging, play a role in its pathogenesis \[[@b30-medscimonit-25-6649],[@b31-medscimonit-25-6649]\]. The reduction of chondrocytes results in the absence of several ECM proteins, and therefore cartilage matrix degradation \[[@b32-medscimonit-25-6649],[@b33-medscimonit-25-6649]\]. An increase in apoptosis in human chondrocytes from normal and OA cartilage was shown to be related to the inflammatory response of the cells \[[@b34-medscimonit-25-6649],[@b35-medscimonit-25-6649]\]. Several intracellular signaling pathways may exacerbate cartilage destruction by stimulating the secretions of catabolic enzymes, including MMP-1, MMP-2, and MMP-3, and other catabolic factors, including COX-2, nitric oxide and nitric oxide synthase, which enhance apoptotic level in OA chondrocytes and thereby the degradation of cartilage ECM \[[@b14-medscimonit-25-6649],[@b36-medscimonit-25-6649]\]. New treatment strategies that reduce chondrocyte apoptosis and promote chondrocyte function are therefore vital.

The catabolic enzymes that are upregulated in IL-1β-induced chondrocytes include MMPs (MMP-1, MMP-3, and MMP-13), ADAMTS-4, and ADAMTS-5 \[[@b37-medscimonit-25-6649]\]. Increases in MMP-3 and MMP-13 in the cartilage are a vital feature of the pathologic progression of OA. These 2 enzymes degrade a wide array of ECM proteins, including collagen II and other proteoglycans, and promote the release of other MMPs \[[@b38-medscimonit-25-6649],[@b39-medscimonit-25-6649]\]. A lentivirus-mediated siRNA targeting ADAMTS-5 inhibited cartilage degeneration *in vivo* experiments \[[@b27-medscimonit-25-6649]\]. CAT is an iridoid glycoside isolated from the root of *Rehmannia*, exerting protective effects against various diseases \[[@b23-medscimonit-25-6649]\]. Recent studies have shown the value of CAT based on its anti-inflammatory, anti-oxidative, as well as anti-apoptotic activities, both *in vitro* and *in vivo* \[[@b40-medscimonit-25-6649]--[@b42-medscimonit-25-6649]\]. CAT protects rat embryonic ventricular myocardial cells against hydrogen-peroxide-induced apoptosis, via regulating the mitochondrial-dependent caspase pathway \[[@b43-medscimonit-25-6649]\]. In this study, IL-1β increased chondrocyte apoptosis by enhancing cellular cleaved caspase-3 levels, whereas CAT had a concentration-dependent anti-apoptotic effect. Similarly, *in vivo* experiments, the expression of cleaved caspase-3 was increased in cells, whereas CAT partially reversed this effect. In addition, our work demonstrated that CAT significantly inhibited MMP-1, MMP-3, MMP-13, ADAMTS-4, ADAMTS-5 mRNA and protein expression, in addition to reducing the degradation of collagen II and aggrecan from the ECM in IL-1β-treated group. In the CAT group, the deposition of proteoglycans in cartilage was markedly higher, and the OARSI score was lower. Together, these results provide strong evidence that the protective effects exerted by CAT treatment include a reduction in chondrocyte apoptosis and restoration of the function of these cells.

The pro-inflammatory cytokines IL-6, 8, IL-1β, and TNF-α play critical roles in the development of OA, and their suppression is a primary treatment strategy in OA \[[@b44-medscimonit-25-6649]\]. Two major pro-inflammatory factors IL-1β and TNF-α have been implicated in synovitis and were shown to activate chondrocytes, resulting in apoptosis and increased expression of genes encoding inflammatory factors, such as COX-2 and MMPs, both of which are essential to the initiation and progression of OA \[[@b45-medscimonit-25-6649],[@b46-medscimonit-25-6649]\]. IL-1β and TNF-α recruit death-related compounds through combination with specific ligands. The result is activation of the apoptotic pathway and thus internucleosomal DNA fragmentation \[[@b20-medscimonit-25-6649],[@b47-medscimonit-25-6649]\]. The inflammatory response exerts critical effects on metabolic processes in the ECM. For example, the inflammation-related upregulation of MMPs leads to progressive matrix catabolism \[[@b48-medscimonit-25-6649]\]. CAT treatment effectively inhibited the IL-1β-induced expression of pro-inflammatory factors.

The involvement of several molecular signaling pathways during the pathophysiology of OA has been reported, and investigations into the mechanisms of OA affecting cartilage chondrocytes are a research hotspot. Members of the NF-κB family are widely expressed transcription factors regulating immunity, cell proliferation, inflammation, apoptosis, and other cellular processes \[[@b49-medscimonit-25-6649]\]. Disturbances caused by harmful factors induce nuclear translocation of the phosphorylated p65 subunit of NF-κB, followed by binding to specific genes and the triggering of their transcription \[[@b50-medscimonit-25-6649]\]. In chondrocytes during the progression of OA, these genes include those encoding several major catabolic enzymes (MMP-1, MMP-2, and MMP-3) and catabolic factors (COX-2 and NO) \[[@b36-medscimonit-25-6649]\]. Thus, NF-κB signaling pathway is required for OA progression. Consequently, therapeutic agents targeting the NF-κB pathway will attenuate the inflammatory response of chondrocytes in OA \[[@b51-medscimonit-25-6649]\]. For example, IκB inducible kinase and IκBα are key members of the NF-κB family, and their repression was shown to attenuate cartilage degeneration \[[@b52-medscimonit-25-6649]\]. In our study, CAT treatment dose-dependently attenuated the level of p65 and the degradation of IκBα, indicating that CAT inhibited the NF-κB pathway. Furthermore, in the immunofluorescence assay, CAT prevented the nuclear translocation of p65, consistent with the results of the western blot.

Conclusions
===========

Our work suggested that CAT treatment attenuates IL-1β-induced inflammatory response and apoptotic level in rat chondrocytes by inhibiting the NF-κB pathway. The result was CAT-mediated suppression of ECM catabolism in OA chondrocytes. *In vivo* experiments also suggested that CAT prevents cartilage degeneration. Our study thus provides important new insights into the mechanisms underlying the protective effect of CAT, as well as support for further studies of CAT in the treatment of OA.
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![CAT decreases apoptotic level in rat chondrocytes. (**A**) The cytotoxic effect of CAT on chondrocytes was tested at various concentrations for 1 day using CCK-8 method. (**B**) CCK-8 assay of CAT-treated chondrocytes induced by IL-1β. (**C, D**) Western blotting and quantification analysis of cleaved caspase-3 among different groups. The values presented are the mean ± standard deviation; significant differences among control and IL-1β group are expressed as ^\#^ *P*\<0.05, ^\#\#^ *P*\<0.01, ^\#\#\#^ *P*\<0.001, and significant differences among CAT+IL-1β group and IL-1β groups are expressed as \* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001, n=5. CAT -- catalpol; CCK-8 -- Cell Counting Kit-8; IL -- interleukin.](medscimonit-25-6649-g001){#f1-medscimonit-25-6649}

![CAT decreases the levels of MMPs stimulated by IL-1β in chondrocytes. (**A--F**) The relative mRNA level of (**A--C**) MMP-1, MMP-3, and MMP-13 were detected by PCR. The protein level of (**D--F**) MMP-1, MMP-3, and MMP-13 were evaluated by ELISA. The values presented are the mean ± standard deviation; significant differences among control and IL-1β group are expressed as ^\#^ *P*\<0.05, ^\#\#^ *P*\<0.01, ^\#\#\#^ *P*\<0.001, and significant differences among CAT+IL-1β group and IL-1β groups are expressed as \* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001, n=5. CAT -- catalpol; MMP -- matrix metalloproteinases; IL -- interleukin; PCR -- polymerase chain reaction; ELISA -- enzyme-linked immunosorbent assay.](medscimonit-25-6649-g002){#f2-medscimonit-25-6649}

![CAT decreases the levels of ADAMTS-4 and ADAMTS-5 stimulated by IL-1β in chondrocytes. (**A--D**) The target mRNA levels of (**A**) ADAMTS-4, (**B**) ADAMTS-5 were detected by PCR. The protein levels of (**C**) ADAMTS-4, (**D**) ADAMTS-5 were evaluated by ELISA. The values presented are the mean ± standard deviation; significant differences among control and IL-1β group are expressed as ^\#^ *P*\<0.05, ^\#\#^ *P*\<0.01, ^\#\#\#^ *P*\<0.001, and significant differences among CAT+IL-1β group and IL-1β groups are expressed as \* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001, n=5. CAT -- catalpol; ADAMTS -- a disintegrin and metalloproteinase with thrombospondin motifs; IL -- interleukin; PCR -- polymerase chain reaction; ELISA -- enzyme-linked immunosorbent assay.](medscimonit-25-6649-g003){#f3-medscimonit-25-6649}

![CAT inhibits IL-1β induced catabolic activities on the level of ECM protein in rat chondrocytes. (**A**) Immunofluorescence assay of collagen II protein (green) and nucleus (blue). (**B, C**) The relative mRNA levels of (**B**) collagen II, (**C**) aggreacan were evaluated by PCR. The values presented are the mean ± standard deviation; significant differences among control and IL-1β group are expressed as ^\#^ *P*\<0.05, ^\#\#^ *P*\<0.01, ^\#\#\#^ P\<0.001, and significant differences among CAT+IL-1β group and IL-1β groups are expressed as \* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001, n=5. CAT -- catalpol; IL -- interleukin; ECM -- extracellular matrix; PCR -- polymerase chain reaction; ELISA -- enzyme-linked immunosorbent assay.](medscimonit-25-6649-g004){#f4-medscimonit-25-6649}

![CAT attenuates the release of pro-inflammatory factors induced by IL-1β in rat chondrocytes. (**A--C**) Western blotting and quantification analysis of IL-6 and TNF-α among different groups. The values presented are the mean ± standard deviation; significant differences among control and IL-1β group are expressed as ^\#^ *P*\<0.05, ^\#\#^ *P*\<0.01, ^\#\#\#^ *P*\<0.001, and significant differences among CAT+IL-1β group and IL-1β groups are expressed as \* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001, n=5. CAT -- catalpol; IL -- interleukin; TNF -- tissue necrosis factor.](medscimonit-25-6649-g005){#f5-medscimonit-25-6649}

![CAT suppressed NF-κB pathway in chondrocytes treated with IL-1β. (**A--C**) Western blotting and quantification analysis of p65 and IκBα among different groups. (**D**) Immunofluorescent assay of p65 (green) and nucleus (blue). The values presented are the mean ± standard deviation; significant differences among control and IL-1β group are expressed as ^\#^ *P*\<0.05, ^\#\#^ *P*\<0.01, ^\#\#\#^ *P*\<0.001, and significant differences among CAT+IL-1β group and IL-1β groups are expressed as \* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001, n=5. CAT -- catalpol; NF-κB -- nuclear factor kappa B; IL -- interleukin.](medscimonit-25-6649-g006){#f6-medscimonit-25-6649}

![(**A--C**) CAT attenuates apoptotic level and ECM degradation in rat cartilage of OA. (**A**) Representative Safranin O staining of the cartilage from each group at 8 weeks post-operation. (**B**) OARSI scores among different groups at 8 weeks. The values presented are the mean ± standard deviation; significant differences among sham and OA group are expressed as ^\#^ *P*\<0.05, ^\#\#^ *P*\<0.01, ^\#\#\#^ *P*\<0.001, and significant differences among OA group and CAT+OA group are expressed as \* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001, n=5. CAT -- catalpol; ECM -- extracellular matrix; OA -- osteoarthritis; OARSI -- Osteoarthritis Research Society International.](medscimonit-25-6649-g007){#f7-medscimonit-25-6649}
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